Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine.
Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, He X, Liu J, McMahan K, Martinot A, Martinez DR, Giffin V, Hope D, Patel S, Sellers D, Sanborn O, Barrett J, Liu X, Cole AC, Pessaint L, Valentin D, Flinchbaugh Z, Yalley-Ogunro J, Muench J, Brown R, Cook A, Teow E, Andersen H, Lewis MG, Boon ACM, Baric RS, Mueller SO, Petsch B, Barouch DH.
Gebre MS, et al.
Nature. 2022 Jan;601(7893):410-414. doi: 10.1038/s41586-021-04231-6. Epub 2021 Nov 18.
Nature. 2022.
PMID: 34794169
Free PMC article.
Although CVnCoV provided partial protection against SARS-CoV-2 challenge, CV2CoV afforded more robust protection with markedly lower viral loads in the upper and lower respiratory tracts. Binding and neutralizing antibody titres were correlated with protective efficacy. .. …
Although CVnCoV provided partial protection against SARS-CoV-2 challenge, CV2CoV afforded more robust protection with markedly lower viral l …